FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328130008> ?p ?o ?g. }

• W4328130008 endingPage "292" @default.
• W4328130008 startingPage "282" @default.
• W4328130008 abstract "Abstract Background People with genital psoriasis may avoid close social interactions (hugs, handshakes, kisses, touching others, or being touched), which can have a significant impact on quality of life. Ixekizumab, an interleukin 17A antagonist, demonstrated rapid and persistent improvement in moderate‐to‐severe genital psoriasis through 52 weeks in a phase 3 trial (IXORA‐Q). Objectives To evaluate general touch avoidance (TA) in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab through 52 weeks in the IXORA‐Q trial. Methods In IXORA‐Q (NCT02718898), adult patients received 80 mg ixekizumab every 2 weeks (IXE Q2W, N = 75) or placebo (PBO, N = 74) for 12 weeks. At Week 12, all patients received open‐label 80 mg ixekizumab every 4 weeks (IXE Q4W) through Week 52, with an opportunity to escalate dosing to Q2W at Weeks 24, 28, or 40. Patients used a numeric rating scale (NRS) to self‐report the degree of TA experienced over the past 2 weeks (score of 0 [not at all] to 10 [very much]). Outcomes included TA NRS score change from baseline and the proportion of patients achieving a TA NRS score of 0 through Week 52. Correlations between TA NRS scores and psoriasis outcomes were also examined. Results Mean (standard deviation) baseline TA NRS score was 2.7 (3.3) for IXE Q2W and 3.0 (3.5) for PBO. Among patients with a baseline TA NRS score >0, mean (standard deviation) change from baseline at Week 52 (where a lower score indicates greater improvement) and the proportion of patients who achieved a TA NRS score of 0 at Week 52 were −4.4 (3.2) [78.0%] for patients treated continuously with ixekizumab (Q2W then Q4W, N = 41) and −4.1 (3.6) [62.5%] for PBO/IXE Q4W ( N = 40). TA NRS score improved in parallel with the majority of psoriasis outcomes examined, with the strongest positive association between the TA NRS score and Dermatology Life Quality Index total score. Conclusions Among patients with moderate‐to‐severe genital psoriasis, ixekizumab treatment achieves continued sustained improvement in general TA to 52 weeks." @default.
• W4328130008 created "2023-03-22" @default.
• W4328130008 creator A5001431413 @default.
• W4328130008 creator A5004761425 @default.
• W4328130008 creator A5006526834 @default.
• W4328130008 creator A5007797742 @default.
• W4328130008 creator A5017726297 @default.
• W4328130008 creator A5020923397 @default.
• W4328130008 creator A5033903141 @default.
• W4328130008 creator A5044898042 @default.
• W4328130008 creator A5045885334 @default.
• W4328130008 creator A5053940783 @default.
• W4328130008 creator A5055048278 @default.
• W4328130008 date "2023-03-21" @default.
• W4328130008 modified "2023-09-25" @default.
• W4328130008 title "Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)" @default.
• W4328130008 cites W1970133878 @default.
• W4328130008 cites W1985525809 @default.
• W4328130008 cites W1985969803 @default.
• W4328130008 cites W1992633930 @default.
• W4328130008 cites W2025869037 @default.
• W4328130008 cites W2096991001 @default.
• W4328130008 cites W2121023063 @default.
• W4328130008 cites W2339525054 @default.
• W4328130008 cites W2766193813 @default.
• W4328130008 cites W2774443073 @default.
• W4328130008 cites W2774683544 @default.
• W4328130008 cites W2789403789 @default.
• W4328130008 cites W2790448266 @default.
• W4328130008 cites W2802931074 @default.
• W4328130008 cites W2889366277 @default.
• W4328130008 cites W2891858343 @default.
• W4328130008 cites W2894504400 @default.
• W4328130008 cites W2899985300 @default.
• W4328130008 cites W2968264741 @default.
• W4328130008 cites W2981214845 @default.
• W4328130008 cites W3016397458 @default.
• W4328130008 doi "https://doi.org/10.1002/jvc2.126" @default.
• W4328130008 hasPublicationYear "2023" @default.
• W4328130008 type Work @default.
• W4328130008 citedByCount "0" @default.
• W4328130008 crossrefType "journal-article" @default.
• W4328130008 hasAuthorship W4328130008A5001431413 @default.
• W4328130008 hasAuthorship W4328130008A5004761425 @default.
• W4328130008 hasAuthorship W4328130008A5006526834 @default.
• W4328130008 hasAuthorship W4328130008A5007797742 @default.
• W4328130008 hasAuthorship W4328130008A5017726297 @default.
• W4328130008 hasAuthorship W4328130008A5020923397 @default.
• W4328130008 hasAuthorship W4328130008A5033903141 @default.
• W4328130008 hasAuthorship W4328130008A5044898042 @default.
• W4328130008 hasAuthorship W4328130008A5045885334 @default.
• W4328130008 hasAuthorship W4328130008A5053940783 @default.
• W4328130008 hasAuthorship W4328130008A5055048278 @default.
• W4328130008 hasBestOaLocation W43281300081 @default.
• W4328130008 hasConcept C126322002 @default.
• W4328130008 hasConcept C142724271 @default.
• W4328130008 hasConcept C159110408 @default.
• W4328130008 hasConcept C16005928 @default.
• W4328130008 hasConcept C168563851 @default.
• W4328130008 hasConcept C183021626 @default.
• W4328130008 hasConcept C1862650 @default.
• W4328130008 hasConcept C204787440 @default.
• W4328130008 hasConcept C27081682 @default.
• W4328130008 hasConcept C2776260265 @default.
• W4328130008 hasConcept C2779745271 @default.
• W4328130008 hasConcept C2779786854 @default.
• W4328130008 hasConcept C2779951463 @default.
• W4328130008 hasConcept C2780564577 @default.
• W4328130008 hasConcept C54355233 @default.
• W4328130008 hasConcept C71924100 @default.
• W4328130008 hasConcept C86803240 @default.
• W4328130008 hasConceptScore W4328130008C126322002 @default.
• W4328130008 hasConceptScore W4328130008C142724271 @default.
• W4328130008 hasConceptScore W4328130008C159110408 @default.
• W4328130008 hasConceptScore W4328130008C16005928 @default.
• W4328130008 hasConceptScore W4328130008C168563851 @default.
• W4328130008 hasConceptScore W4328130008C183021626 @default.
• W4328130008 hasConceptScore W4328130008C1862650 @default.
• W4328130008 hasConceptScore W4328130008C204787440 @default.
• W4328130008 hasConceptScore W4328130008C27081682 @default.
• W4328130008 hasConceptScore W4328130008C2776260265 @default.
• W4328130008 hasConceptScore W4328130008C2779745271 @default.
• W4328130008 hasConceptScore W4328130008C2779786854 @default.
• W4328130008 hasConceptScore W4328130008C2779951463 @default.
• W4328130008 hasConceptScore W4328130008C2780564577 @default.
• W4328130008 hasConceptScore W4328130008C54355233 @default.
• W4328130008 hasConceptScore W4328130008C71924100 @default.
• W4328130008 hasConceptScore W4328130008C86803240 @default.
• W4328130008 hasFunder F4320307758 @default.
• W4328130008 hasIssue "2" @default.
• W4328130008 hasLocation W43281300081 @default.
• W4328130008 hasOpenAccess W4328130008 @default.
• W4328130008 hasPrimaryLocation W43281300081 @default.
• W4328130008 hasRelatedWork W2078674248 @default.
• W4328130008 hasRelatedWork W2207365337 @default.
• W4328130008 hasRelatedWork W2556463364 @default.
• W4328130008 hasRelatedWork W2802386347 @default.
• W4328130008 hasRelatedWork W2897210759 @default.

• next